When compared with BMT, umbilical cord blood transplantation (UCBT) is associated with a lower rate of engraftment and delayed hematological/immunological recovery. This leads to increased risk of TRM in the early post transplantation period due to infection. Acute GVHD, although occurring less frequently in UCBT compared with BMT, is also significantly associated with increased rate of early TRM. BM MSCs are known to support normal in vivo hematopoiesis, and co-transplantation of MSCs has been shown to enhance engraftment of human cord blood hematopoietic cells in nonobese diabetic/SCID mice. In 13 children with hematological disorders (median age 2 years) undergoing UCBT, we cotransplanted paternal, HLA-disparate MSCs with the aim of improving hematological recovery and reducing rejection. We observed no differences in hematological recovery or rejection rates compared with 39 matched historical controls, most of whom received G-CSF after UCBT. However, the rate of grade III and IV acute GVHD was significantly decreased in the study cohort when compared with controls (P ¼ 0.05), thus resulting in reduced early TRM. Although these data do not support the use of MSCs in UCBT to support hematopoietic engraftment, they suggest that MSCs, possibly because of their immunosuppressive effect, may abrogate life-threatening acute GVHD and reduce early TRM.
, LM Ball 2, 6 , AM Cometa Since the first successful transplantation of hematopoietic stem cells (HSCs) derived from umbilical cord blood (UCB) from an HLA-identical sibling in 1988, 1 the number of patients receiving UCB transplantation (UCBT), in particular from an unrelated donor (UD), has steadily increased. [2] [3] [4] [5] [6] [7] Compared with BMT, UCBT offers the clinical advantages of absence of risks for the donor, reduced risk of transmitting infections, reduced incidence and severity of GVHD and, for transplants from UDs, rapid availability of cryopreserved cells, with the median time for a successful donor search being o1 month. 2, 3, [8] [9] [10] [11] [12] Results of UCBT from either an HLA-compatible sibling or from a UD have been reported to be comparable with those obtained in children transplanted with BM cells. 1, [13] [14] [15] However, in comparison with pediatric patients transplanted with BM cells from a matched UD, children receiving an unrelated UCBT, most being HLA disparate, have both delayed kinetics of hematopoietic recovery and increased risk of TRM in the early post transplantation period, mainly attributable to a higher risk of infectious complications. 16, 17 Strategies aimed at improving engraftment and reducing TRM in UCBT recipients, such as infusion of two units in the same recipient, ex vivo expansion of UCB HSCs and intrabone injection of cord blood cells, have been recently proposed. [18] [19] [20] Besides these approaches, the co-infusion of MSCs together with UCB HSCs could be an alternative option for optimizing the engraftment of donor cells. Indeed, MSCs, which are multipotent cells capable of differentiation into several mesenchymal lineages, 21, 22 possess peculiar properties of immunomodulation on all cells involved in the immune response. [23] [24] [25] [26] [27] Moreover, Noort et al. 28 showed in a nonobese diabetic/SCID mouse model that co-transplantation of MSCs facilitated, both in BM and peripheral blood, UCB HSC engraftment, especially when low numbers of UCB-derived CD34 þ cells were infused.
MSCs have been already successfully used in the clinical setting to treat acute GVHD, as well as to accelerate hematopoietic recovery in patients given either BM or peripheral blood HSCs. [29] [30] [31] [32] [33] [34] In particular, we have recently shown that in patients given a T-cell-depleted PBSC transplantation from an HLA-haploidentical relative, coinfusion of donor-derived MSCs with HSCs was safe and was able to reduce the risk of graft failure. 34 We report on 13 children undergoing either a related or UD UCBT, in whom we co-infused BM-derived, ex vivoexpanded, parental MSCs. Results in these patients were compared with those of a group of 39 historical controls consisting of children given either related or UD UCBT.
Patients and methods

Patients
A total of 13 pediatric patients (median age 2 years, range 0. [8] [9] [10] [11] [12] [13] [14] with hematological disorders were enrolled in this study and received co-transplantation of UCB cells and parental-derived MSCs between May 2006 and January 2008. The results of these 13 patients were compared with those obtained in a group of 39 historical controls (median age 4 years, range 0. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] transplanted in one of the three centers (Pavia, Leiden and Stockholm) and matched as closely as possible for original disease and type of UCB donor used. Details on the study population and controls are reported in Table 1 .
The study was approved by the ethics committees and written informed consent was obtained from all patients or from their parents/legal guardians and from MSC donors. Donor-recipient histocompatibility was determined by serological typing for HLA-A and -B and by highresolution DNA typing for HLA-DRB1.
14 Of the 13 study patients, 2 (15%) received UCBT from an HLA-identical sibling, whereas the remaining 11 were transplanted from an UD who was perfectly matched in four (31%) cases, or had a single or double HLA disparity in six (46%) and one (8%) case, respectively. In the control group, 8 (20%) patients received UCBT from a related HLA-identical donor, whereas 31 underwent an UD UCBT, from a perfectly matched donor in 5 (13%) cases, a 5/6 matched donor in 25 (64%) and a 4/6 matched donor in 1 (3%) case, respectively.
Preparative regimens varied according to patient age and disease and the center protocols (see also Table 1 ). In both groups, GVHD prophylaxis was based on the use of CYA alone in case of transplantation from an HLA-identical sibling, and CYA together with steroids for patients receiving UCBT from an UD, 14 with the exception of three patients in the control group who received CYA and MTX. Pre-transplantation antithymocyte globulin was administered to all recipients of an UD UCBT. Details on patient and UCB unit characteristics, conditioning regimens and GVHD prophylaxis, as well as the median number of UCB cells infused are reported in Table 1 . There was no significant difference between patients and controls in terms of age, gender, underlying disease and disease status at transplantation, UCB donor used, conditioning regimen and type of GVHD prophylaxis administered, number of total nucleated cells (TNCs) and CD34 þ cells infused (see also Table 1 for details).
In the control group, the majority of children (69%) received G-CSF after transplantation to facilitate neutrophil recovery, whereas only 23% of the study patients were administered the growth factor (Po0.05).
Preparation of MSCs
Approximately 5 weeks before the scheduled date of transplantation, MSCs were isolated and expanded ex vivo from 50 to 70 mL parental BM, as previously described (see also Supplementary Information for details). 34 Criteria for MSC release for clinical use were as follows: spindle-shaped morphology, absence of contamination by pathogens, viability X80% and an immune phenotype characterized by the expression of CD73, CD90 and CD105 surface molecules and the absence of CD34, CD45 and CD31. MSCs were infused at passage (P) 2 or 3 to reduce the potential risk of in vitro transformation of the cells, and when at least 1 Â 10 6 /kg of recipient body weight were available; the median dose of MSCs infused was 1.9 (range 1-3.9) Â 10 6 /kg of recipient body weight, at a final concentration of 1-2 Â 10 6 cells/mL. Either conventional karyotype or molecular karyotype through array-comparative genomic hybridization was performed on the cell products before infusion and resulted normal.
Co-transplantation of MSCs and UCB cells
On day 0, while strictly monitoring vital signs, the study patients received parental MSCs i.v. through a central venous catheter, followed by the infusion, 4 h later, of UCB cells. The MSC donor was the father in 12 (92%) out of 13 patients enrolled. The median number of UCB TNCs and CD34 þ cells infused in the study patients was 5.7 (range 1.6-13.3) Â 10 7 /kg recipient weight and 2.2 (range 0.6-6) Â 10 5 /kg, respectively. The median number of UCB TNCs and CD34 þ cells given to controls was 6.6 (range 1.4-11.6) Â 10 7 /kg recipient weight and 2.6 (range 0.5-6.6) Â 10 5 /kg, respectively (see also Table 1 for further details).
Statistical analysis
The report date for the analysis was 1 August 2009, that is, the day at which the centers locked up data on patient outcomes. Patients were censored at the time of death or last follow-up. Definitions of outcome are detailed in Supplementary Information. Probability of OS, leukemiafree survival and EFS were estimated using the KaplanMeier product-limit method and expressed as percentage and 95% confidence interval (95% CI). 35 Probabilities of disease recurrence, acute and chronic GVHD, graft failure and TRM were calculated as cumulative incidence curves (and 95% CI) to adjust the analysis for competing risks. 36, 37 For acute and chronic GVHD, death and relapse were the competing events. For relapse, non-relapse mortality was the competing event, whereas for TRM, relapse represented the competing event.
The Student's t-test, Fisher's exact test and w 2 with Yates' correction were used to assess differences between study and historical control groups. The significance of differences between EFS curves was estimated using the log-rank test (Mantel-Cox), whereas Gray's test was used to assess differences in relapse risk, TRM and acute and chronic GVHD. 38 A P-value of p0.05 was considered significant.
Statistical analysis was performed using the STATA package (StataCorp College Station, TX, USA) 39 and the R 2.5.0 software package (http://www.R-project.org). 40 
Results
In all parental donors, expansion of a sufficient number of BM-derived MSCs (X1 Â 10 6 /kg) was successful; study patients received a median number of 1.9 Â 10 6 MSCs/kg (range 1-3.9). No MSC infusion-related toxicity was observed.
Neutrophil and platelet engraftment and graft rejection Two (15%) study patients, both transplanted with a 5/6 matched UD UCB unit, experienced primary graft failure. They were both re-transplanted. The first patient, who was affected by juvenile myelomonocytic leukemia, received a second UCBT from a different 5/6 matched UD, whereas the second patient, who was suffering from hemophagocytic lymphohistiocytosis, underwent T-cell-depleted PBSC transplantation from his HLA-haploidentical father. Both patients are currently alive without any sign of GVHD and are considered to be successfully cured of their original disorder. The number of TNCs, CD34 þ cells and MSCs infused in patients with sustained engraftment and in those who experienced primary graft failure in the study group were super-imposable (data not shown). The cumulative incidence of graft failure in the study group was 15% (95% CI 4-55), whereas that of controls was 3% (95% CI 0-18; P ¼ NS, see also Figure 1 for details), with one patient affected by AML and transplanted from a 5/6 matched UD experiencing primary graft failure in the control group.
For study patients who engrafted, the median time to reach neutrophil recovery was 30 days (range 17-42), whereas that of controls was 28 days (range 13-44; P ¼ NS). The median time to reach a platelet count above 20 Â 10 9 /L and 50 Â 10 9 /L was 32 days (range 14-85) and 38 days (range 33-113), respectively, in patients receiving MSCs, whereas that of controls was 36 days (range 18-91; P ¼ NS) and 49 days (range 20-110; P ¼ NS), respectively.
Acute and chronic GVHD The cumulative incidence of grade II-IV acute GVHD in patients receiving MSCs was 31% (95% CI 14-70), whereas that of controls was 41% (95% CI 28-60; P ¼ NS). However, none of the study patients developed grade III and IV acute GVHD, whereas the cumulative incidence of the most severe forms of this complication in controls was 26% (95% CI 15-44; P ¼ 0.05, see also Figure 2 ).
In the study group, four (31%) patients developed grade II acute GVHD; they were all transplanted from an UD. All four patients responded to additional either single (one case) or multiple (three cases) infusions of parental and/or third-party MSCs performed at different times after UCBT, after failing first-or second-line immunosuppressive treatment (see also Table 2 for details). In the control group, six (15%), seven (18%) and three (8%) patients developed grade II-IV acute GVHD, respectively. The three children with grade IV acute GVHD died because of GVHD progression, not responsive to several lines of immunosuppressive therapy (not including MSC treatment).
In all, 10 study patients and 30 controls, surviving more than 100 days after transplantation, were evaluated for the occurrence of chronic GVHD. None of the MSC-treated patients at risk developed chronic GVHD, whereas three (10%) children experienced chronic GVHD in the control group, which was extensive in two cases. All patients with chronic GVHD had previously had grade III acute GVHD. The cumulative incidence of chronic GVHD was 0 and 11% (95% CI 4-31; P ¼ NS) in study patients and controls, respectively.
TRM
One patient in the MSC group died of transplantationrelated complications (HHV6 encephalitis) before engraftment (day þ 33); he was affected by hemophagocytic lymphohistiocytosis and received an UD UCBT from a 5/6 matched unit. Eight patients in the control group experienced TRM at a median time of 51 days (range 28-159) after the allograft; they were all transplanted from an UD that was 5/6 matched in seven cases and 6/6 matched in the remaining one. The cumulative incidence of TRM was 8% (95% CI 1-51) and 21% (95% CI 11-38; P ¼ NS) in the study patients and controls, respectively. Acute GVHD and infections, either bacterial or fungal, were the most common causes of transplantation-related death in controls. Figure 2 Grade III and IV acute GVHD after UCBT (study patients vs historical matched controls). Significant reduction in acute severe GVHD was observed in children receiving co-transplantation of UCBT and MSCs (P ¼ 0.05).
OS, EFS and leukemia-free survival
Ten study patients are alive, at a median follow-up of 28 months (range [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] ; in the control group, 25 patients are alive with a median follow-up of 42 months (range 16-134). The Kaplan-Meier estimate of OS at 3 years is 63% (95% CI 43-97) and 64% (95% CI 48-79; P ¼ NS) in study patients and controls, respectively. All surviving patients, both in the MSC and in the control group, have a Karnofsky/Lansky score of 100%. Three (23%) study patients, affected by ALL, experienced disease recurrence at 6, 8 and 16 months after transplantation. Out of the three, two who were transplanted from an HLA-identical sibling, have received a second transplantation using BM-derived HSCs from the same donor. One of the two is currently alive, in remission, with sustained donor engraftment, whereas the other developed chronic GVHD with obstructive bronchiolitis, which was the cause of death at 15 months after the second transplantation. The third patient experiencing leukemia relapse was affected by T-lineage ALL and was transplanted from a 5/6 matched UD. He subsequently received a haploidentical T-cell-depleted PBSC transplantation from his brother and died 2 months later because of grade IV acute GVHD and adenovirus disseminated infection. In the control group, nine (23%) patients, seven affected by ALL and two by AML, experienced relapse at a median follow-up of 6 months (range 2-17). Six of them died because of disease progression. The cumulative incidence of relapse at 3 years was 25% (95% CI 9-67) and 23% (95% CI 13-42; P ¼ NS) in study patients and controls, respectively.
The Kaplan-Meier estimates for leukemia-free survival and EFS at 3 years for study patients were 67% (95% CI 41-94) and 48% (95% CI 19-78), respectively, whereas those of controls were 56% (95% CI 40-72; P ¼ NS) and 53% (95% CI 37-69; P ¼ NS), respectively.
Chimerism analysis of ex vivo-expanded MSCs derived from recipient BM at 3-month intervals up to 1 year after UCBT using PCR for informative donor recipient polymorphisms 41 did not show any evidence of MSC donor cells. Hematopoietic chimerism is detailed in Table 3 .
Discussion
The stem cell niche in the BM represents the most appropriate habitat for HSC, providing a spatial structure that enables both self-renewal and differentiation of hematopoietic progenitors. The cells forming the marrow niche consist of macrophages, fibroblasts, adipocytes, osteoprogenitors, endothelial cells, reticular cells and MSCs, which, together, contribute to support hematopoiesis through crosstalk with HSC. 42 Preclinical studies indicate that co-transplantation of human MSCs is able to promote engraftment of UCB-derived HSC in nonobese diabetic/SCID mice and in fetal sheep. The enhancing effect involved cells of myeloid, lymphoid and megakaryocytic lineages, with this finding showing that the engraftmentpromoting effect of MSCs was not lineage specific and it was particularly prominent when the dose of HSCs was low. 28, 43 Altogether, these data suggest that co-infusion of MSCs could be a promising strategy to optimize the engraftment of UCB progenitors, especially in the presence of HLA disparities between the donor and the recipient, and have provided the rationale for testing the capacity of these cells to facilitate hematological recovery in human patients given allogeneic UCBT.
MSCs have been initially used in a single patient transplanted with UCB cells with the aim of improving the outcome of double-unit UCBT. 44 In this patient, MSCs were administered without clinical adverse effects and, interestingly, the single-unit predominance described after multiple cord blood unit transplantation was abrogated. 44 More recently, the results of a preliminary, phase I-II trial aimed at establishing the safety of ex vivo culture-expanded allogeneic human MSCs from haploidentical related donors co-transplanted during UD UBCT were reported. 45 Eight children were enrolled in the trial, receiving a median MSC number of 2.1 Â 10 6 (range 0.9-5.0)/kg body weight. Infusion of ex vivo culture-expanded haploidentical MSCs proved to be safe and patients had a neutrophil recovery at a median time of 19 days after the allograft. 45 The results on our 13 children undergoing UCBT and treated with haploidentical BM-derived ex vivo-expanded MSCs from a parent support the safety of the approach, as we observed neither infusion toxicity nor ectopic tissue formation.
Compared with UD BMT recipients, children receiving UCBT have a reduced rate of sustained donor engraftment and delayed hematopoietic recovery. Slow neutrophil recovery, as well as impaired immune reconstitution, increases early TRM, 9, 13, 16, 17, 46 and thus reduces the overall effectiveness of this approach. The infused cell dose is an important factor related to outcome, both in terms of engraftment and overall survival. 2, [8] [9] [10] 16, 17 Children receiving a higher cell dose are less likely to experience fatal complications. 7, [15] [16] [17] 46, 47 In particular, the Minnesota group showed that recipients receiving a TNC dose before cryopreservation of o2.5 Â 10 7 /kg or CD34 þ infused cell dose of o1.7 Â 10 5 /kg had inferior neutrophil engraftment and slower recovery. 15 There were no differences in the median number of either TNCs or CD34 þ cells infused between our patients given MSCs and control groups of children receiving UCBT, with the majority of children receiving doses greater than the minimum threshold suggested by the Minnesota recommendations. 15 This may have obscured any positive effect of MSCs to accelerate neutrophil and plt recovery, as in the animal model the positive effect of MSCs on hematopoietic recovery was more evident when co-infused with low number of CD34 þ cells. 28, 43 The co-infusion of haploidentical MSCs did not improve the cumulative incidence of graft failure in the study group when compared with historical matched controls. This observation is in contrast to our recently published report of co-transplantation of haploidentical MSCs in children receiving T-cell-depleted HLA-disparate PBSC transplantation from a relative. 34 This difference may be related to the mechanisms underlying graft failure in the setting of haploidentical SCT vs CBT. Graft dysfunction in UCBT may be inherent to the low numbers of HSC infused and/or to altered homing mechanisms, whereas graft failure in the haploidentical setting may be mainly because of immunemediated mechanisms. Moreover, any positive effect of MSCs in children undergoing UCBT in our study may have been also obscured by the use of G-CSF in historical controls. The result of our study would, however, indicate that the use of haploidentical MSCs to overcome delayed engraftment or to prevent graft rejection in children undergoing UCBT cannot be justified.
Several previously published reports aimed at comparing the outcome of UCBT and BMT from UD in children with hematological disorders showed reduced incidence of GVHD in recipients of UCBT when compared with children given BMT. 16, 17, 46, [48] [49] [50] However, acute GVHD, even in the most severe form, can also occur in patients transplanted with UCB cells, significantly contributing to early TRM. In these series of UCBT performed in children, the incidence of grade I and II and grade III and IV acute GVHD ranged between 30 and 50% and between 10 and 20%, respectively. 16, 17 The rates of acute GVHD observed in our historical control group was similar to that reported in these published data obtained from large cohorts of children undergoing UCBT. In our children receiving MSCs, no severe (that is, grade III and IV) acute GVHD was observed in contrast to the historical matched controls (26%), and no patient died because of GVHD-associated TRM. These findings suggest that the co-infusion of MSCs at the time of transplantation sufficiently reduced donor T-cell alloreactivity. Similarly, no study patient developed chronic GVHD compared with 10% of historical controls. In view of these observations, we conclude that MSC co-infusion may be an effective way of reducing GVHDrelated TRM in UCBT recipients. This would be particularly useful in children undergoing UCBT for nonmalignant disease, as well as in patients given doubleunit UCBT, in whom the rates of acute GVHD have been reported to be increased compared with single-unit UCBT. 18 Moreover, the observation that our four patients treated with parental MSCs who developed grade II acute GVHD responded to additional doses of MSCs suggests that infusion of ex vivo-expanded MSCs, regardless of the type of donor, is a possible effective treatment in steroidresistant acute GVHD, 31 although a greater number of patients should be studied to draw firm conclusions on this issue.
The 3-year cumulative incidence of leukemia relapse was comparable in study patients and controls, with this finding suggesting that the co-infusion of parental MSCs in UCBT recipients is not associated with an increased risk of disease recurrence. Moreover, the incidence of viral infection/ reactivation, as well as of other fungal or bacterial infections, did not differ between the two groups. This latter observation indicates that patients receiving MSC infusion do not seem to be exposed to an increased risk of developing infectious complications after transplantation.
In summary, our study shows that the co-infusion of haploidentical BM-derived MSCs is feasible and safe and significantly reduces the incidence of life-threatening acute GVHD and GVHD-associated TRM.
